• Read more about A022104

Short Title: JANUS

This phase II trial compares the effect of irinotecan versus oxaliplatin after long-course chemoradiation in patients with stage II-III rectal cancer. Combination chemotherapy drugs, such as FOLFIRINOX (fluorouracil, irinotecan, leucovorin, and oxaliplatin), FOLFOX (leucovorin, fluorouracil, oxaliplatin, and irinotecan), and CAPOX (capecitabin and oxaliplatin) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Study Number:

A022104

Study Status:

Enrolling

Treatment Agent:

Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin

Resources and Links

National Clinical Trial Identified Number: NCT05610163

Disease:

• Locally Advanced Rectal Carcinoma

Study Phase:

II

researchcancer@cooperhealth.edu

Index Extra:

GI, gastro, rectal

Hide from Search:

Off

Physician Name:

• Jamin C. Morrison, MD, MBA

Department:

• Hematology and Medical Oncology

• Read more about PRAGMATICA

Short Title: PRAGMATICA

This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. 

Study Number:

S2302

Study Status:

Enrolling

Treatment Agent:

Pembrolizumab, Ramucirumab

Resources and Links

National Clinical Trial Identified Number: NCT05633602

Disease:

• Recurrent Lung Non-Small Cell Carcinoma,
• Stage IV Lung Cancer

Study Phase:

III

researchcancer@cooperhealth.edu

Index Extra:

lung, thoracic

Hide from Search:

Off

Physician Name:

• Polina Khrizman, MD

Department:

• Hematology and Medical Oncology,
• Lung Cancer

• Read more about SURVENT

Short Title: SURVENT 

The trial’s primary aim is to determine if patients undergoing endoscopic eradication therapy will demonstrate less neoplastic progression and a lower incidence of esophageal adenocarcinoma compared to patients undergoing surveillance. 

Study Number:

SURVENT

Study Status:

Enrolled

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT05753748

Disease:

• Barrett’s Esophagus with Low-grade Dysplasia,
• Esophageal Adenocarcinoma

Study Phase:

Not Applicable

researchcancer@cooperhealth.edu

Index Extra:

Esophageal, head and neck, Dysplasia, Barrett’s, Esophagus, gastro

Hide from Search:

Off

Physician Name:

• Anthony Infantolino, MD, FACP, FACG, AGAF, FASGE

Department:

• Digestive Health Institute (Gastroenterology)

• Read more about SOROCk

Short Title: SOROCk

This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Study Number:

CC008

Study Status:

Enrolling

Treatment Agent:

Not Applicable

Resources and Links

National Clinical Trial Identified Number: NCT04251052

Disease:

• Ovarian Carcinoma

Study Phase:

Not Applicable

ResearchCancer@CooperHealth.edu

Index Extra:

Ovarian, gyn, Gynecologic

Hide from Search:

Off

Physician Name:

• David P. Warshal, MD, FACOG

Department:

• Gynecologic Cancer Center

• Read more about DECREASE

Short Title: DECREASE

This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type.

Study Number:

EA2182

Study Status:

Enrolling

Treatment Agent:

Capecitabine, Fluorouracil, Mitomycin

Resources and Links

National Clinical Trial Identified Number: NCT04166318

Disease:

• Anal Basaloid Carcinoma,
• Anal Canal Cloacogenic Carcinoma,
• Anal Canal Squamous Cell Carcinoma,
• Anal Margin Squamous Cell Carcinoma

Study Phase:

II

researchcancer@cooperhealth.edu

Index Extra:

GI, Anal

Hide from Search:

Off

Physician Name:

• Megan Mezera, MD

Department:

• Radiation Oncology,
• Hematology and Medical Oncology

• Read more about SAMURAI

Short Title: SAMURAI

This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic).

Study Number:

GU012

Study Status:

Enrolling

Treatment Agent:

Avelumab, Axitinib, Cabozantinib, Ipilimumab, Lenvatinib, Nivolumab, Pembrolizumab

Resources and Links

National Clinical Trial Identified Number: NCT05327686

Disease:

• Metastatic Renal Cell Carcinoma,
• Unresectable Renal Cell Carcinoma

Study Phase:

II

researchcancer@cooperhealth.edu

Index Extra:

GU, Renal

Hide from Search:

Off

Physician Name:

• Gary A. Eastwick, MD

Department:

• Radiation Oncology

• Read more about TROPION- BREAST 03

Short Title: TROPION- BREAST 03

The study will investigate the efficacy and safety of Dato-DXd with or without durvalumab when compared with ICT (capecitabine and/or pembrolizumab) in participants with stage I to III TNBC who have residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvant systemic therapy.

Study Number:

D926XC00001

Study Status:

Enrolling

Treatment Agent:

Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab

Resources and Links

National Clinical Trial Identified Number: NCT05629585

Disease:

• Stage I-III Triple-negative Breast Cancer

Study Phase:

III

ResearchCancer@CooperHealth.edu

Index Extra:

breast

Hide from Search:

Off

Physician Name:

• Kamel Abou Hussein, MD

Department:

• Breast Cancer Center,
• Breast Cancer,
• Hematology and Medical Oncology